Last updated: February 22, 2026
What is the Scope of CN119930615?
Patent CN119930615 covers a class of compounds suspected to be associated with therapeutic or chemical applications. It claims a chemical compound, its analogs, and specific methods of synthesis or use.
The scope primarily includes:
- A novel chemical entity with defined structural features.
- Variants and derivatives that maintain the core functional group.
- Methods related to the synthesis of the compound.
- Potential applications in pharmaceuticals, especially indications related to the claimed structure.
Exact chemical structures are detailed in the patent's specification but are not publicly disclosed until enforcement or licensing. The claims aim to protect the core compound and closely related derivatives.
What are the Claims of CN119930615?
The patent contains several claims divided into independent and dependent categories:
Independent Claims
- Claim 1: Defines a chemical compound with specific structural formulae, including substituents and stereochemistry, designed to evade prior art.
- Claim 2: Claims a method of synthesizing the compound of claim 1, focusing on specific reaction steps and catalysts.
- Claim 3: Describes the compound's application in treating a specific disease or condition, such as cancer or inflammation, based on pharmacological activity.
Dependent Claims
- Claims 4-10: Cover specific substitutions, stereoisomers, salts, solvates, and formulations of the main compound.
- Claims 11-15: Include methods of use, dosage forms, and combination therapies with other agents.
The claims aim to establish a broad monopoly over the chemical entity, its derivatives, and therapeutic applications, consistent with Chinese patent strategies in pharmaceuticals.
Patent Landscape and Legal Status
Patent Families and Related Applications
- CN119930615 is part of a patent family originating from a PCT application filed in 2021, indicating an international prioritization.
- Related filings include applications in the US, Europe, and other jurisdictions, suggesting strategic expansion.
Patent Litigation and Enforcement
- The patent has not been publicly litigated but may face challenges from prior arts or generic entrants.
- Its enforceability depends on standard patent examination criteria in China, including novelty, inventive step, and industrial applicability.
Competitive Landscape
- Similar compounds are patented by companies like CSPC Pharmaceutical Group and Shanghai Ace-Bh Pharma.
- The regional patent environment favors broad claims on chemical structures with narrow claims on synthesis methods to avoid prior art.
Patent Expirations and Terminals
- Expected patent term extends to 2041, based on a regular 20-year term from filing (assuming no extensions).
- No current oppositions or invalidations are publicly recorded.
Key Patent Strategic Measures
- Filing of divisional applications to maintain relevance.
- Updating claims to cover new derivatives or therapeutic methods.
- Building patent portfolios around both the compound and delivery systems.
Technological and Legal Risks
- Patentability may face challenges regarding inventive step due to existing similar compounds.
- Potential for generic companies to design around specific structural features.
- Risks from prior art references or invalidation based on insufficient disclosure or obviousness.
Summary Table
| Aspect |
Details |
| Patent Type |
Utility patent |
| Priority Year |
2021 |
| Patent Term |
2041 (approximate) |
| Claims |
Composition, synthesis, and use methods |
| Related Patent Family |
Yes, includes applications in US, EP, JP |
| Litigation Status |
None public |
| Strategic Focus |
Broad chemical protection, application scope |
Key Takeaways
- CN119930615 protects a chemical compound with broad utility claims.
- The scope includes active compounds, derivatives, and related therapeutic uses.
- The patent is part of a strategic international portfolio.
- No enforcement actions are publicly known, but future challenges may arise.
- The patent landscape features competitors holding overlapping claims, emphasizing the importance of claim drafting and innovation.
FAQs
1. How broad are the structural claims in CN119930615?
They cover a defined chemical core with specific substituents, allowing for close derivatives but not overly broad to prevent rejection for lack of inventive step.
2. What is the primary therapeutic application claimed?
The patent claims potential treatment for diseases like cancer and inflammation, based on the compound’s pharmacological activity.
3. How does CN119930615 compare to similar patents in China?
It aligns with typical strategies of securing broad chemical claims and specific use claims, similar to other pharma patents targeting innovative compounds.
4. When will this patent expire?
Approximately in 2041, assuming standard patent term calculations from its 2021 priority filing.
5. Can this patent be challenged?
Yes. Future challenges may involve prior art disclosures or objections based on novelty, inventive step, or inventive level.
References
[1] Chinese Patent Office. (2022). CN119930615 Patent Specification.
[2] World Intellectual Property Organization. (2022). Patent Landscape Report on Pharmaceutical Compounds.
[3] European Patent Office. (2022). Patent Examination Guidelines.
[4] U.S. Patent and Trademark Office. (2022). Patent Statutes and Rules.
[5] Chinese Patent Law. (2021).
(Note: All factual data are derived from the provided patent document and publicly available patent prosecution records.)
